Enanta Pharmaceuticals Inc
ENTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001177648
No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Enanta Pharmaceuticals Inc changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 160 | 1 | 147 | −12 |
| Shares | 19.7M | 22.8K | 19.2M | −460.0K (−2.3%) |
| Value | $1.02B | $1.18M | $894.5M | −$126.6M (−12.4%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Braidwell LP | 325,838 | $15.2M | 0.51% |
| Camber Capital Management LP | 110,000 | $5.12M | 0.18% |
| Man Group plc | 13,698 | $637.2K | 0.00% |
| Ergoteles LLC | 11,876 | $552.5K | 0.02% |
| Gsa Capital Partners LLP | 11,057 | $514.0K | 0.06% |
| Kiwi Wealth Investments Limited Partnership | 8,380 | $389.8K | 0.03% |
| Cornercap Investment Counsel Inc | 5,742 | $267.1K | 0.05% |
| Y-Intercept (Hong Kong) Ltd | 4,385 | $204.0K | 0.03% |
| Simplex Trading, LLC | 250 | $11.0K | 0.00% |
| Dark Forest Capital Management LP | 9 | $419 | 0.00% |
Sold out (22)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Ra Capital Management, L.P. | 896,724 | $46.5M |
| Fairmount Funds Management LLC | 469,264 | $24.3M |
| Foresite Capital Management V, LLC | 42,250 | $2.19M |
| Schonfeld Strategic Advisors LLC | 23,415 | $1.22M |
| HRT Financial LP | 18,673 | $968.0K |
| Victory Capital Management Inc | 17,330 | $899.0K |
| Campbell & CO Investment Adviser LLC | 13,006 | $675.0K |
| ExodusPoint Capital Management, LP | 12,804 | $664.0K |
| HighVista Strategies LLC | 11,286 | $585.0K |
| AlphaCrest Capital Management LLC | 10,700 | $555.0K |
| Tudor Investment Corp Et Al | 10,327 | $536.0K |
| Susquehanna Fundamental Investments, LLC | 6,291 | $326.0K |
| Aquatic Capital Management LLC | 6,100 | $316.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 5,110 | $265.0K |
| Trexquant Investment LP | 4,882 | $253.0K |
| Everence Capital Management Inc | 4,260 | $221.0K |
| Mutual of America Capital Management LLC | 3,875 | $201.0K |
| Point72 Hong Kong Ltd | 2,169 | $113.0K |
| Macquarie Group Ltd | 178 | $21.0K |
| Meeder Asset Management Inc | 90 | $5.00K |
| Ellevest, Inc. | 79 | $4.00K |
| Quantbot Technologies LP | 39 | $2.00K |
Not filed for Q4 2022 yet (1)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Foresite Capital Opportunity Management V, LLC | 22,750 | $1.18M |